NRIX
Nurix Therapeutics, Inc.
$23.97
+0.06 (+0.25%)
At close · Jul 2
Market Cap
$2.48B
Shares
103,405,813
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.97
Open$24.00
Day$23.22–24.22
52W$8.20–24.88
Avg vol 30d2.8M
Short int20.0M · 19.4% float · 4.9d
Short vol46%
Last earningsApr 8, 2026
DataJul 2020–Jul 2026
Filing10-Q · Apr 8
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+53% above
+
Price vs 50-day avg
+37% above
−
RSI (14)
81 · overbought
+
MACD trend
positive
+
52-week position
95% · near high
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $18 › 200d $16 — 50d above 200d
+
Institutional flow
2 of 195 funds reported for Jun 30 · net +61 sh shares · +1 new
−
Insider flow
Net -$743.9K over 90 days · 100% sells
−
Short interest
19.37% of float · ▲ +3.6% MoM · 4.9 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
195 holders — near 3-yr high, broad support
Fundamentals
Fair
+
Revenue growth
+99% Y/Y
−
EPS growth
−6% Y/Y
−
Free cash flow
$-263.5M
+
Balance sheet
net cash $247.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 9, 2026
Est · unconfirmed
· in 1 wks
FQ3-26 quarter ends
~Aug 30, 2026
Est
filed Apr 8, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+53% above
Bullish
Price vs 50-day avg
+37% above
Bullish
RSI (14)
81 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
95% · near high
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $18 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
2 of 195 funds reported for Jun 30 · net +61 sh shares · +1 new
Insider flow
Distributing
Net -$743.9K over 90 days · 100% sells
Short interest
Rising
19.37% of float · ▲ +3.6% MoM · 4.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
195 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $24 · 95%
52-wk high $25
vs 200-day avg +53%
vs 50-day avg +37%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRIX
this stock
Nurix Therapeutics, Inc.
|
$2.48B | +26.4% | +99.3% | — | 19.4% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRIX | +6.7% | +54.8% | +28.7% | -1.2% | +26.4% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +5.3% | +56.1% | +20.6% | -0.9% | +17.1% |